Last reviewed · How we verify
Hormone receptor-positive breast cancer — Treatment Landscape & Competitive Intelligence
1 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| PF-07850327, ARV-471, vepdegestrant | pf-07850327-arv-471-vepdegestrant | Pfizer | Selective Estrogen Receptor Modulators (SERMs), Selective Estrogen Receptor Degraders (SERDs), Selective Estrogen Receptor Covalent Antagonists (SERCAs) | Estrogen Receptor (ER) |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- Pfizer · 1 drug in Hormone receptor-positive breast cancer
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Hormone receptor-positive breast cancer:
- Hormone receptor-positive breast cancer treatment updates — RSS
- Hormone receptor-positive breast cancer treatment updates — Atom
- Hormone receptor-positive breast cancer treatment updates — JSON
Cite this brief
Drug Landscape (2026). Hormone receptor-positive breast cancer — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/hormone-receptor-positive-breast-cancer. Accessed 2026-06-10.
Related
- Hormone receptor-positive breast cancer full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing